Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT ID
NCT06760039
Phase
PHASE1 / PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • R-CMOP Regimen
  • R-CHOP Regimen
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Aged ≥18,≤80 years, both male and female.
  • Pathologically confirmed DLBCL
  • No prior treatment for DLBCL.
  • There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →